How To Get Clean Teat After 2 Days Without Meth

J Pharmacol Exp Ther. 2022 Jul; 338(1): 31–36.

A Method to Quantify Illicit Intake of Drugs from Urine: Methamphetamine

Received 2022 January 11; Accustomed 2022 Mar 28.

Abstract

Qualitative urinalysis can verify abstinence of drug misuse but cannot detect changes in drug intake. For drugs with slow elimination, such as methamphetamine (MA), a single episode of abuse can outcome in up to v days of positive urine drug screens. Thus, interventions that produce substantial decreases in drug use only practice not attain near complete abstinence are classified as ineffective. Using nonpharmacologic doses of deuterium-labeled 50-methamphetamine (l-MA-d₃) we take adult a simple, robust method that reliably estimates changes in MA intake. Twelve subjects were dosed with 5 mg of l-MA-d₃ daily and challenged with 15, xxx, and 45 mg of nonlabeled d-MA (d-MA-d₀) after reaching plasma steady condition of l-MA-d₃. Urinary concentration ratios of d-MA-d₀ to l-MA-d₃ provided clear separation of the administered doses with every bit little as 15-mg dose increments. Administered doses could non be resolved using d-MA-d₀ concentrations lone. In determination, the urinary [d-MA-d₀]:[l-MA-d_iii] provides a quantitative, continuous measure of illicit MA exposure. The method reliably detects small, clinically relevant changes in illicit MA intake from random urine specimens, is amenable to deployment in clinical trials, and can be used to quantify patterns of MA abuse.

Introduction

Epidemics of methamphetamine (MA) corruption and habit are occurring throughout the world (Schifano et al., 2007; Degenhardt et al., 2008; McKetin et al., 2008), fueled past the illicit synthesis of 197 to 624 metric tons of illicit amphetamine-like drugs per year, enough for more than 10 billion 30-mg MA doses (http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf). Some of these abusers become the addicts who create social, wellness, and crime consequences that affect all levels of guild (Watanabe-Galloway et al., 2009). Thus, there is a pressing need to develop treatments for MA addiction. Unfortunately, despite an intense attempt over the concluding xx years, no medications accept been proven constructive for the treatment of MA addiction (Karila et al., 2022).

Results of qualitative urine toxicology tests are the primary objective outcome measures for near antiaddiction trials, including trials for MA addiction. Urine immunoassays that are sensitive (but not specific) and cheap and tin exist deployed in the clinic are commonly used in these trials. To eliminate faux-positive results drug identity is confirmed and a urine drug concentration measured using sensitive and specific assay methods that e'er include mass spectrometry (MS). Although these methods yield precise and authentic urine concentrations, several factors, including historic period, hydration status, urine pH, and urine flow, all make back-extrapolation from urine concentration to the quantity of drug abused difficult, if not incommunicable. As a consequence, the results of urine drug tests are only scored equally a time series of binary outcomes of "positive" or "negative."

Forbearance is the goal of addiction treatments, and qualitative urine toxicology is exceedingly sensitive for detecting drug use in normally abstinent individuals. However, it is not sensitive in detecting either reductions or cursory periods (up to ii–3 days) of abstinence in individuals. Thus, extremely large reductions in abuse (perhaps up to 90%) are needed before fifty-fifty a modest reduction in urinalysis-positive results will be evident and the treatment volition be accepted every bit effective (National Constitute on Drug Abuse/College on Problems of Drug Dependence, 1999). This degree of stringency may exist the reason for failure of all treatments for MA habit tested to appointment. If new treatments for stimulant abuse are unlikely to yield sudden, total abstinence, and then qualitative methods that are unable to measure less than total abstinence are not likely to be useful in selecting drug or other treatment candidates that may decrease just not eliminate illicit intake. Considering the growing list of failed trials for MA dependence, developing methods that allow nonbinary continuous interpretation of drug intake has become essential.

To determine illicit intake nosotros have been testing the utility of giving small, pharmacologically inactive oral doses of deuterium-labeled drugs or metabolites that have a pharmacokinetic profiles similar to the abused drug of interest. We then decide urinary concentration ratios of unlabeled (illicit and self-administered) to deuterium-labeled drug (or metabolite) to make it at an estimate of intake and exposure to the addictive drug. The method is analogous to using an internal standard in analytic chemistry.

In this article nosotros present laboratory validation of a method for quantitatively estimating exposure to MA. When used in a clinical trial this method changes a binary to a continuous measure and will allow evaluation of partial efficacy of a putative treatment. To appraise MA intake we used trideuterated fifty-MA with deuterium labeling on the methyl grouping. In prior work we accept shown that this level of deuteration does not modify the pharmacology of MA in humans (Harris et al., 2003). l-MA [also notated R-(−)-MA] is the less pharmacologically active isomer compared with d-MA [also notated Due south-(+)-MA]. In work leading to this study we established that 5-mg oral doses of 50-MA are completely absorbed, accept no measurable subjective or cardiovascular effects, and are hands detected in urine (Li et al., 2022).

Materials and Methods

Subjects.

Twelve healthy, nondependent, MA-using subjects (eight men, four women; mean age 31 ± 10 years; mean weight 72 ± thirteen kg; 83% white) participated in this study. To be included subjects had to have used MA for at least i yr with more than than 20 lifetime exposures but non be MA-dependent by criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Participants were in good wellness as judged by medical test, laboratory tests (including hematologic, hepatic, and renal serum chemistries), urinalysis, and ECG. The study was canonical past the California Pacific Medical Center and University of California, San Francisco institutional review boards. The study was carried out in accordance with the Declaration of Helsinki.

Study Design.

A stock-still-sequence, open-label design with sequential outpatient-inpatient phases was used. Oral doses of 5 mg of 50-MA-d₃ were administered for 14 days. On days 1 to vii subjects were outpatients. During this menstruum, a single oral dose of 5-mg l-MA-d_iii was administered every morning time under straight supervision. Subjects were admitted to the research ward on day 7. On study days 8, x, and 12, a series of ascending intravenous d-MA-d₀ doses of xv, 30, and 45 mg were given. Each d-MA-d₀ dose was administered over 1 min under infusion pump command (Harvard Apparatus Inc., Holliston, MA). The 15-mg dose was given every bit a single infusion. The thirty-mg dose was given every bit two fifteen-mg infusions with doses separated by one h. The 45-mg dose was given as five ix-mg infusions each separated by ane h. This blueprint was designed to simulate a d-MA binge.

Before each outpatient 50-MA-d_iii dose pharmacodynamic effects were assessed. Subjects were monitored for 1 h afterward dosing and had Visual Analog Scale measures and vital signs measured before discharge. During the inpatient stage, vital signs and subjective-effect measures were obtained often. During infusions subjective and cardiovascular measures were obtained before and 15 min after each infusion and at 0.5, i, one.5, 2, four eight, 24, and 48 h subsequently the last infusion.

Blood Collection.

Venous blood samples (approximately 7 ml) were obtained using sterile techniques from an indwelling intravenous catheter. During the outpatient phase trough plasma levels were obtained earlier dosing. On infusion days plasma samples for d-MA-d₀ and 50-MA-d_three levels were obtained before and at 0.25, 0.5, ane, 2, four, 8, 24, and 48 h after dosing. For the 30- and 45-mg doses, additional plasma samples were obtained immediately before and 15 min afterwards each infusion and at 0.5, 1, 2, 4, 8, 24, and 48 h after the last dose.

Urine Collection.

During the inpatient phase subjects voided as needed. All voided urine was collected with time, volume, and urine pH of each individual sample recorded.

Bioassay.

d-MA-d₀ and l-MA-d₃ in plasma and urine were measured past combined gas chromatography (GC)-MS, using dl-MA-d_ix as the internal standard. The analytes were extracted from the respective biofluids, converted to the trifluoroacetyl amide derivatives, separated by gas chromatography on a Restek Rtx-200 MS analytical column (Restek, Bellefonte, PA), and detected by mass spectrometry operated in the chemical ionization way, using isobutane as the reagent gas. The molecular ion species (Chiliad + H)⁺, one thousand/z 246, 249, and 255, were monitored for the trifluoroacetyl amides of MA-d₀, MA-d₃, and MA-d₉, respectively. Interday accurateness for the measurement of MA-d₀ and MA-d_three in urine ranged from 108 to 109%, respectively, at the 5 ng/ml limit of quantitation, and from 100 and 105%, respectively, at 2500 ng/ml. The respective coefficients of variation were 12 and 7.5% at the limit of quantitation and 4.five and v.3% at 2500 ng/ml. In all cases MA-d₃ could easily be quantified against a background of MA-d₀.

Pharmacokinetic Analysis.

Pharmacokinetic data for d-MA-d₀ and l-MA-d₃ were analyzed using nonlinear mixed-effect models implemented using the program NONMEM (version seven; NONMEM Project Group, Academy of California, San Francisco). A population pharmacokinetic model (based on complete data from 12 subjects) of oral repeated 50-MA-d₃ dosing indicates that pharmacokinetic steady state reached within 5 days of daily oral doses of v mg of l-MA-d_three. The full model will exist presented in a separate commodity.

Urinary Data Analysis.

The unlabeled-to-labeled MA urine concentration ratio, which we formally notate every bit [d-MA-d₀]:[50-MA-d_three], was adamant for each nerveless urinary sample. Linear discriminant assay was used to examination whether [d-MA-d₀]:[fifty-MA-d₃]differentiated between administered doses of d-MA-d₀. Classifier accurateness was evaluated past subject area-based leave-i-out cross-validation. Each bailiwick's data were classified based on a grooming prepare consisting of the other discipline'south data. Because of the incomplete systemic distribution of MA, urine specimens collected within the first 5 h of d-MA-d₀ dosing were not used to railroad train the classifier but were used as test data. A divide analysis was conducted for urine specimens collected more 24 h later dosing, because the concentration ratio is affected by connected daily oral fifty-MA-d₃ administration at 24 h. McNemar'due south test was used to compare accuracy between classification methods. A linear regression model was used to draw the human relationship betwixt urinary [d-MA-d₀]:[fifty-MA-d₃] and the respective MA dose. Prediction bands of 95% were calculated to reflect the dubiety about future observations and indicate the distribution within which 95% of future observations are expected to fall (Dalgaard, 2008). All computations were performed using R.

Results

Safety and Tolerability.

All MA doses tested were well tolerated, and no serious agin events occurred. There were no measurable pharmacodynamic furnishings after any of the l-MA-d_iii doses; d-MA produced expected increases in eye rate, blood pressure, and subjective effects.

Urinary Concentration Ratio, [d-MA-d₀]:[fifty-MA-d₃].

A total of 589 urine samples were nerveless; 331 between 0 and 24 h and 238 between 24 and 48 h later doses of d-MA-d₀. In Fig. 1 we testify urine d-MA-d₀ concentrations plotted confronting time. Hither, the urine concentrations after the three doses of d-MA-d₀ (analogous to increasing amounts of illicit intake) overlap substantially and cannot be separated by dose. This finding is consequent with a previous study in MA addicts presenting for treatment where MA urine concentrations varied from undetectable to 300,000 ng/ml. Despite a concentration range spanning half-dozen orders of magnitude, MA urine concentrations did not permit prediction of the corporeality of illicit intake (Batki et al., 2000).

Urine d-MA-d₀ concentrations after 15, xxx, and 45 mg of d-MA-d₀ by individual subject.

In Fig. 2 we present the urinary [d-MA-d₀]:[l-MA-d₃] plotted against time. Now dose-dependent increases tin can easily be visually discriminated. Visual (and statistical) discrimination is peculiarly evident at times more than 5 h later on the first d-MA-d₀ dose. As described above, classification methods based on the dependent variables of time, urine [d-MA-d₀], or urine [d-MA-d₀]:[l-MA-d_three] every bit predictors were adult. The overall accuracy and sensitivity/specificity for each dose condition derived from each classification method are summarized in Table 1. For urine samples collected from v h later on d-MA-d₀ dosing through the adjacent 50-MA-d_three dose, the classification accuracy was 91% using urine [d-MA-d₀]:[fifty-MA-d₃], which was a significant (p < 0.001) improvement over the 54% accuracy using urine [d-MA-d₀] solitary. Classification based on both urine [d-MA-d₀]:[fifty-MA-d₃] and time since dosing further improved accurateness to 96% (p < 0.001), and this is displayed in Fig. three. From 24 to 48 h classifier accuracy using the urine [d-MA-d₀]:[l-MA-d₃] vicious to 60.0% for 15-mg dose differences, simply if the analysis was restricted to 30-mg dose increments accuracy remained robust at 84.6% and was a meaning improvement over the 72.8% accuracy obtained using urine [d-MA-d₀] alone (p < 0.01). From 24 to 48 h, including time as a predictor did not significantly ameliorate nomenclature accuracy (83.four%; p = 0.77).

Urine concentration ratio, [d-MA-d₀]:[l-MA-d₃], after 5 mg of l-MA-d₃ and xv, thirty, and 45 mg of d-MA-d₀ past individual subject.

Table 1

Performance of unlike nomenclature methods

Fourth dimension Menstruum	Predictors	Overall Accuracy	Sensitivity			Specificity
			15 mg	30 mg	45 mg	fifteen mg	thirty mg	45 mg
h		%	%	%	%	%	%	%
5–24	[d-MA-d0]	54	76	50	36	75	66	90
v–24	[d-MA-d0]:[l-MA-d3]	91	95	87	91	96	93	97
5–24	[d-MA-d0]:[fifty-MA-d3], time	96	95	97	95	99	95	100
24–48	[d-MA-d0]:[l-MA-d3]	60	78	39	63	73	74	92
24–48 (15 vs. 45 mg)	[d-MA-d0]	73	96		46	46		96
24–48 (xv vs. 45 mg)	[d-MA-d0]:[l-MA-diii]	85	98		69	69		98
24–48 (15 vs. 45 mg)	[d-MA-d0]:[l-MA-dthree], fourth dimension	83	96		69	69		96

Classification of urine samples into different dosage weather condition based on the method using [d-MA-d₀]:[l-MA-d₃] and fourth dimension since dosing as predictors.

The ratio of d-MA-d₀ to l-MA-d_three doses in this study were 3 (xv mg of MA-d₀:5 mg of MA-d₃), half-dozen (30 mg of MA-d₀:five mg of MA-d₃), and 9 (45 mg of MA-d₀:5 mg of MA-d₃). When the dose ratios were treated as continuous variables instead of categorical variables, the ratios of doses were linearly related to urinary [d-MA-d₀]:[l-MA-d₃] (Fig. four; urinary ratio = − 0.44 + 0.62 × dose ratio; R ^two = 0.8198).

Relationships between urine [d-MA-d₀]:[l-MA-d_iii] and d-MA-d₀/l-MA-d₃ dose ratio. The line within the box is the median, the area within the box contains the second and tertiary quartiles, and whiskers include information points that autumn within 1.five times the interquartile range. The solid black line is the regression line. Dashed lines are 95% prediction bands.

Discussion

We nowadays a unproblematic, robust method of using pharmacologically inactive oral doses of l-MA-d₃ to estimate the illicit MA amount consumed. With this method, useful estimates of MA exposure can exist made from spontaneously voided urine specimens within a relatively broad time window.

For both detection and confirmation, urine toxicology tests classify a sample as positive if information technology contains an amount equal to or greater than the lowest concentration of the drug that tin can exist reliably detected in the urine after a single dose. This degree of sensitivity minimizes the possibility of missing an episode of drug use (Dolan et al., 2004). However, it likewise minimizes the sensitivity of these tests for detecting decreases in drug taking. For example, because of its deadening elimination, depression concentrations of MA tin be detected in urine for up to 7 days afterwards a single oral dose of 30 mg (Valentine et al., 1995) or up to 60 h after a unmarried 15-mg smoked or intravenous dose (Cook et al., 1993). These information suggest that the highly sensitive urine toxicology methods used in addiction trials may overdetect MA abuse, probably decreasing the power of trials to place effective treatments. Overdetection of corruption likewise exists for other abused drugs such as cocaine, amphetamine, and marijuana. For example, based on urine benzyolecgonine concentrations, Preston et al. (1997) institute that a cyclical design of cocaine abuse was not detected using binary result assignments of urine results. In a study of recently incarcerated drug abusers, amphetamine remained detectable in urine for more than 48 h in all subjects; one subject had positive urine results for 9 days (Smith-Kielland et al., 1997).

Self-reports of drug utilise are commonly used to assess the quantity of illicit intake. These measures tin be inaccurate because illicit drug abusers often consume impure, diluted drugs and apply dosing methods with incomplete bioavailability (oral and nasal) or where variable amounts of drug are destroyed (i.e., pyrolysis with smoked drugs). Our method estimates the bioavailable fraction of the illicit dose, the amount associated with pharmacologic activeness and toxicity.

The detection window (the length of time in days later on the terminal use of a drug) that sequentially collected urine samples continue to produce positive drug test results can exist affected by many variables. Pharmacological factors include dose, route of administration, duration of use (acute or chronic), and charge per unit of emptying. Several factors affect elimination including age, organ function, urine pH, hydration condition, and polymorphisms of drug-metabolizing enzymes (http://www.ndci.org/sites/default/files/ndci/DCR.VI__2.pdf). For example, urine acidification dramatically increases MA elimination. Because of the aggregating of drug in deep compartments, longer detection windows are more than likely in chronic abusers, a grouping oft targeted in clinical trials. Analytical factors such as the sensitivity of the test (cutoff concentration) and the method'south specificity (the actual drug and/or metabolite that is being detected) can also affect the detection window (Jaffee et al., 2008). Labeled and unlabeled MA have identical absorption, distribution, metabolism, and elimination; thus our method controls for most of these intraindividual and interindividual factors.

There are 2 clear advantages of using urine concentration ratios of non-labeled to deuterium labeled drugs or metabolites equally a quantitative endpoint in clinical trials. First, modest reductions in drug misuse can be tracked, allowing better estimates of therapeutic drug efficacy or rational selection of combination therapies. In dissimilarity to currently bachelor qualitative technologies urine concentration ratios yield a continuous outcome measure. Our information suggest than the urinary [d-MA-d₀]:[fifty-MA-d₃] can differentiate as piffling as fifteen-mg increases in exposure to d-MA-d₀ in a wide detection window. The ratio is directly related to the total d-MA-d₀ exposure without beingness affected past administration regimen (single or multiple) at least for samples obtained from 1 h after the terminal unlabeled dose. These properties make the urinary [d-MA-d₀]:[l-MA-d₃] an attractive biomarker of illness severity and therapeutic response that tin be easily adapted for MA treatment trials. It is noteworthy that the analytic engineering needed to quantify the isotopes of MA (GC-MS or liquid chromatography-MS) is already widely available and currently used to confirm qualitative results. The just change required in electric current analytic technologies will be apply of a differently deuterated internal standard; both MA-d₃ and MA-d₉ are commercially available as internal standards for MA assays. Second, quantitative estimates of drug exposure volition allow better stratification of the severity of disease. Other instruments that grade the severity of habit, such as the Addiction Severity Index, primarily reflect slowly irresolute factors, such equally employment, relationships, and legal status. Our method offers a finer temporal resolution. Logically, the severity of an addictive disorder is related to the corporeality of drug exposure; the ability to quantify exposure to illicit MA will let a ameliorate assessment of the human relationship between drug misuse and affliction.

There are limits to our method. Commencement, subjects need to take l-MA-d_three but may not do so. In upcoming trials we plan to coadminister l-MA-d₃ with the handling medication. Subjects with no l-MA-d_iii in urine tin be assumed not to be adherent to the treatment medication; thus our method allows evaluation of adherence equally well as outcome. Second, we only tested intravenous MA administration, and urinary ratios may be slightly different if MA is abused by routes with slower absorption (oral and nasal). Samples collected immediately later abuse of MA, while drug continues to be absorbed and distributed, may atomic number 82 to inaccurate estimates of use. However, for samples obtained in the emptying phase urine concentration ratios should remain robust in estimating the captivated driveling dose. Many participants in drug treatment attend group or individual counseling; obtaining urine samples after therapy visits may attenuate this limitation. Finally, our method may increase the cost of conducting trials. We judge the costs of synthesizing deuterated MA and preparing individual dose units containing fifty-MA-d₃ are $five to x per dose. There should be no additional costs if confirmatory assays using mass spectrometry are used. Thus, for an viii-week trial where subjects are dosed daily with deuterated drug the additional price would exist $280 to 560 per subject. This price is balanced past the increased ability from use of a continuous primary outcome variable, probably decreasing the number of subjects needed and ultimately the trial price. In addition, the toll of rejecting potentially efficacious therapies caused past inadequate endpoints is unaffordable.

In determination, assistants of pharmacologically inactive doses of oral fifty-MA-d₃ followed by quantifying the urine [d-MA-d₀]:[50-MA-d₃] permits estimation of the corporeality of MA abuse from a single random urine specimen. Quantification of drug exposure from easily obtained biological specimens volition be useful in developing new treatments for MA addiction, understanding the patterns of abuse, and determining compliance with pharmacotherapies during clinical trials. Introduction of a continuous outcome measure may be a substantial improvement from the current qualitative binary upshot measures used to assess MA abuse. Finally, development of similar methods for other addictive drugs is possible.

This work was supported past the National Institutes of Health National Institute of Drug Corruption [Grants P50-DA018179, DA012521, P30-DA12393]; the National Institutes of Health National Institute of Allergy and Infectious Diseases Extramural Activities [Grant R01-AI50587]; and the National Institutes of Wellness National Institute of General Medical Sciences [Grant GM26696].

Article, publication engagement, and commendation information can exist found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.111.179176.

ABBREVIATIONS:

MA

methamphetamine

fifty-MA-d₃

deuterium-labeled l-methamphetamine

d-MA-d₀

nonlabeled d-MA

GC

gas chromatography

MS

mass spectrometry.

Authorship Contributions

Participated in research pattern: Galloway and Mendelson.

Conducted experiments: Galloway, Baggott, Lopez, and Mendelson.

Contributed new reagents or analytic tools: Everhart.

Performed data analysis: Li and Coyle.

Wrote or contributed to the writing of the manuscript: Li, Verotta, Baggott, and Mendelson.

References

• Batki SL, Moon J, Delucchi 1000, Bradley M, Hersh D, Smolar Due south, Mengis M, Lefkowitz E, Sexe D, Morello L, et al. (2000) Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine handling. Preliminary assay. Ann NY Acad Sci 909:260–263 [PubMed] [Google Scholar]
• Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M. (1993) Pharmacokinetics of methamphetamine cocky-administered to human being subjects by smoking Southward-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21:717–723 [PubMed] [Google Scholar]
• Dalgaard P. (2008) Introductory Statistics with R. Springer, New York [Google Scholar]
• Degenhardt 50, Roxburgh A, Black E, Bruno R, Campbell Thou, Kinner Southward, Fetherston J. (2008) The epidemiology of methamphetamine utilise and harm in Australia. Drug Alcohol Rev 27:243–252 [PubMed] [Google Scholar]
• Dolan K, Rouen D, Kimber J. (2004) An overview of the utilise of urine, pilus, sweat and saliva to detect drug employ. Drug Alcohol Rev 23:213–217 [PubMed] [Google Scholar]
• Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. (2003) The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 74:475–486 [PubMed] [Google Scholar]
• Jaffee WB, Trucco E, Teter C, Levy S, Weiss RD. (2008) Focus on booze & drug abuse: ensuring validity in urine drug testing. Psychiatr Serv 59:140–142 [PubMed] [Google Scholar]
• Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud Yard, Batki SL. (2010) Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 69:578–592 [PMC free article] [PubMed] [Google Scholar]
• Li Fifty, Lopez JC, Galloway GP, Baggott MJ, Everhart T, Mendelson J. (2010) Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Ther Drug Monit 32:504–507 [PMC gratis commodity] [PubMed] [Google Scholar]
• McKetin R, Kozel North, Douglas J, Ali R, Vicknasingam B, Lund J, Li JH. (2008) The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 27:220–228 [PubMed] [Google Scholar]
• National Plant on Drug Corruption/College on Issues of Drug Dependence (1999) Consensus statement on evaluation of event of pharmacotherapy for substance abuse/dependence study. National Institute on Drug Corruption/College on Bug of Drug Dependence Meeting; 1999 April 23–24; Washington, DC [Google Scholar]
• Preston KL, Silverman Thousand, Schuster CR, Cone EJ. (1997) Assessment of cocaine use with quantitative urinalysis and interpretation of new uses. Addiction 92:717–727 [PubMed] [Google Scholar]
• Schifano F, Corkery JM, Cuffolo G. (2007) Smokable ("ice", "crystal meth") and non smokable amphetamine-blazon stimulants: clinical pharmacological and epidemiological bug, with special reference to the United kingdom. Ann Ist Super Sanita 43:110–115 [PubMed] [Google Scholar]
• Smith-Kielland A, Skuterud B, Mørland J. (1997) Urinary excretion of amphetamine later on termination of drug abuse. J Anal Toxicol 21:325–329 [PubMed] [Google Scholar]
• Valentine JL, Kearns GL, Sparks C, Letzig LG, Valentine CR, Shappell SA, Neri DF, DeJohn CA. (1995) GC-MS conclusion of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of bear witness supporting the established forensic guidelines for methamphetamine confirmation. J Anal Toxicol xix:581–590 [PubMed] [Google Scholar]
• Watanabe-Galloway S, Ryan S, Hansen One thousand, Hullsiek B, Muli V, Malone AC. (2009) Furnishings of methamphetamine abuse beyond private users. J Psychoactive Drugs 41:241–248 [PubMed] [Google Scholar]

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126645/

Posted by: hillreyer2001.blogspot.com

Share this post